

smart Health Report

An Insightful Health Analytics Report
for Easier Understanding



Prepared For

Mr MR.DUMMY

M 23


Name
Mr MR.DUMMY

Patient ID
8052846

Gender
M

Age
23

Health Summary



DIABETES MONITORING

Test Name	Result
Glycosylated Hemoglobin (HbA1c)	7
Please Watchout	



Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 25, 2024, 06:30 PM.
Patient ID / UHID : 8052846/RCL7249282	Barcode No : HY585687
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Whole blood EDTA	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Polycystic Ovary Syndrome (PCOS) Panel - Comprehensive Plus

HbA1C (Glycosylated Haemoglobin)

Glycosylated Hemoglobin (HbA1c) <i>HPLC</i>	7	%	< 5.7
Estimated Average Glucose	154.2	mg/dL	Refer Table Below

Interpretation:

Interpretation For HbA1c% As per American Diabetes Association (ADA)

Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Age < 19 years Goal of therapy: <7.5

Note:

1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled. 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate

Comments :

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)	HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126	12	298
8	183	14	355
10	240	16	413



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 08, 2024, 11:46 AM.
Patient ID / UHID : 8052846/RCL7249282	Barcode No : ZC664006
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : FLUORIDE F	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Glucose Fasting (BSF)

Glucose Fasting <i>Hexokinase</i>	75.0	mg/dL	<100
--------------------------------------	------	-------	------

Interpretation:

Status	Fasting plasma glucose in mg/dL
Normal	<100
Impaired fasting glucose	100 - 125
Diabetes	≥126

Reference : American Diabetes Association

Comment :

Blood glucose determinations are commonly used as an aid in the diagnosis and treatment of diabetes. Elevated glucose levels (hyperglycemia) may also occur with pancreatic neoplasm, hyperthyroidism, and adrenal cortical hyper function as well as other disorders. Decreased glucose levels (hypoglycemia) may result from excessive insulin therapy insulinoma, or various liver diseases.

Note

- The diagnosis of Diabetes requires a fasting plasma glucose of $>$ or $=$ 126 mg/dL or a random / 2 hour plasma glucose value of $>$ or $=$ 200 mg/dL with symptoms of diabetes mellitus.
- Very high glucose levels ($>$ 450 mg/dL in adults) may result in Diabetic Ketoacidosis.



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name	: Mr MR.DUMMY	Sample Collected	: Apr 26, 2024, 01:00 PM
DOB/Age/Gender	: 23 Y/Male	Report Date	: May 08, 2024, 01:00 PM.
Patient ID / UHID	: 8052846/RCL7249282	Barcode No	: ZC664008
Referred By	: Dr. Dr. X	Report Status	: Final Report
Sample Type	: Serum		

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Prolactin (PRL)

Prolactin CMIA	18.5	ng/mL	3.46 - 19.40
-------------------	------	-------	--------------

Interpretation:
Note:
 1. Since prolactin is secreted in a pulsatile manner and is also influenced by a variety of physiologic stimuli, it is recommended to test 3 specimens at 20-30 minute intervals after pooling.
 2. Major circulating form of Prolactin is a nonglycosylated monomer, but several forms of Prolactin linked with immunoglobulin occur which can give falsely high Prolactin results.
 3. Macroprolactin assay is recommended if prolactin levels are elevated, but signs and symptoms of hyperprolactinemia are absent or pituitary imaging studies are normal

Clinical Use
 · Diagnosis & management of pituitary adenomas
 · Differential diagnosis of male & female hypogonadism

Increased Levels
 · **Physiologic:** Sleep, stress, postprandially, pain, coitus
 · **Systemic disorders:** Chest wall or thoracic spinal cord lesions, Primary / Secondary hypothyroidism, Adrenal insufficiency, Chronic renal failure, Cirrhosis
 · **Medications: Psychiatric medications** like Phenothiazine, Haloperidol, Risperidone, Domperidone, Fluoxetine, Amitriptylene, MAO inhibitors etc.,

Antihypertensives: Alphamethyldopa, Reserpine, Verapamil

Opiates: Heroin, Methadone, Morphine, Apomorphine

Cimetidine / Ranitidine
 · Prolactin secreting pituitary tumors: Prolactinoma, Acromegaly
 · Miscellaneous: Epileptic seizures, Ectopic secretion of prolactin by non-pituitary tumors, pressure / transection of pituitary stalk, macroprolactinemia
 · Idiopathic

Decreased levels
 · Pituitary deficiency: Pituitary necrosis / infarction
 · Bromocriptine administration
 · Pseudohypoparathyroidism



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
 Processing Lab :-

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 08, 2024, 01:00 PM.
Patient ID / UHID : 8052846/RCL7249282	Barcode No : ZC664008
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Serum	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Testosterone Total

Testosterone Total ECLIA	480.0	ng/dL	Males(20-49 years of age) 249 - 836 Males (>=50 years of age) 193 - 740
-----------------------------	-------	-------	--

Interpretation:

Reference values for Males (7-18 years) characterized by Tanner Stage

Tanner Stage	5-95th percentiles (ng/dL)
1	< 2.5
2	< 2.5 - 432
3	64.9 - 778
4	180 - 763
5	188 - 882

Reference values for females (8-18 years) characterized by Tanner Stage

Tanner Stage	5-95th percentiles (ng/dL)
1	<2.5 - 6.1
2	<2.5 - 10.4
3	<2.5 - 23.7
4	<2.5 - 26.8
5	4.6 - 38.3

Note

- All applications that require measurement of very low level of testosterone (eg hypogonadal men, children, virilization or intersex disorders in women etc) recommended test is Testosterone total, Ultrasensitive
- LC-MS/MS is the gold standard for steroid hormone assays due to increased sensitivity & specificity as compared to immunoassays

Clinical Use

Assessment of testicular function in males

Increased levels

- Precocious puberty (Males)
- Androgen resistance
- Testotoxicosis
- Congenital Adrenal Hyperplasia

Decreased levels

- Delayed puberty (Males)
- Gonadotropin deficiency
- Testicular defects
- Systemic diseases

Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 08, 2024, 12:59 PM.
Patient ID / UHID : 8052846/RCL7249282	Barcode No : ZC664007
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : INSULIN F	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Insulin Fasting

Insulin (Fasting) ECLIA	15.6	µU/mL	<25
----------------------------	------	-------	-----

Interpretation:
Note
 1. A single random blood sample for insulin may provide insufficient information due to wide variation in the time responses of insulin levels and blood glucose.
 2. Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino acids, growth hormone and catecholamines.
 3. Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with bovine or porcine insulin.

Clinical Utility
 · Evaluation of fasting hypoglycemia
 · Evaluation of Polycystic Ovary syndrome
 · Classification of Diabetes mellitus
 · Predict Diabetes mellitus
 · Assessment of Beta cell activity
 · Select optimal therapy for Diabetes
 · Investigation of insulin resistance
 · Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism, Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism
Decreased levels - Untreated Type I Diabetes mellitus



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
 Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 08, 2024, 01:00 PM.
Patient ID / UHID : 8052846/RCL7249282	Barcode No : ZC664008
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Serum	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

17-HYDROXYPROGESTERONE (17-OHP), SERUM

17-HYDROXYPROGESTERONE (17-OHP), SERUM CLIA	0.95	ng/mL	
--	------	-------	--

Interpretation:

PHASES OF MENSTRUATION	REFERENCE RANGE IN ng/ml
Follicular phase	0.1 - 0.8
Luteal phase	0.6 - 2.3
Ovulatory phase	0.3 - 1.4
Post ACTH	<3.2
Late pregnancy	2.0 - 12.0
Menopause	0.13 - 0.51
New Born Girls	
1 Month	2.4 - 16.8
2 Month	1.6 - 9.7
3 Month	0.1 - 3.1
New Born Boys	
1 Month	0.0 - 8.0
2 Month	3.6 - 13.7
3 Month	1.7 - 4.0
Children 3 to 14 Years old	0.1 - 1.7
Normal Males	0.5 - 2.1

Comment
 17-Hydroxyprogesterone (17-OHP) is produced by both the adrenal cortex and gonads. It is of intense clinical interest because it is the immediate precursor to 11-desoxycortisol which is produced by 21-hydroxylation of 17-OHP. In congenital 21-hydroxylase deficiency, the most common variety of Congenital Adrenal Hyperplasia (CAH), 17-OHP is secreted in excess quantity. It is moderately elevated in the 11-β-hydroxylase deficiency as well. Measurement of 17-OHP is therefore valuable in the initial diagnosis of CAH. The concentration of 17-OHP in newborn varies with age, weight, prematurity and twinning. Premature, sick or stressed infants have higher 17-OHP values leading to false positive screen results. Antenatal corticosteroid treatment may reduce 17-OHP levels resulting in false negative screen

Usage
 Marker for Adrenal 21-Hydroxylase enzyme deficiency in
 · Infants with features of Adrenal insufficiency like hypotension, vomiting, fever, hypoglycemia and hyperkalemia
 · Infants with ambiguous genitalia
 · Women with clinical evidence of possible androgen excess, most prevalent in Ashkenazi Jews who have a high prevalence of non-classical 21-hydroxylase deficiency

Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
 Processing Lab :-

Patient Name	: Mr MR.DUMMY	Sample Collected	: Apr 26, 2024, 01:00 PM
DOB/Age/Gender	: 23 Y/Male	Report Date	: May 08, 2024, 01:00 PM.
Patient ID / UHID	: 8052846/RCL7249282	Barcode No	: ZC664008
Referred By	: Dr. Dr. X	Report Status	: Final Report
Sample Type	: Serum		

Test Description	Value(s)	Unit(s)	Reference Range
17 OHP LEVELS IN ng/mL	REMARKS		
<2.0	Diagnosis of CAH unlikely provided sample given in the morning (8-10AM) during follicular phase in menstruating women		
2 - 10	Indeterminate, ACTH Stimulation test recommended to differentiate between PCOS and Non classical CAH		
>10	Highly suggestive of CAH		



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
 Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 08, 2024, 01:00 PM.
Patient ID / UHID : 8052846/RCL7249282	Barcode No : ZC664008
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Serum	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

LH / FSH Ratio

Luteinising Hormone-LH <i>ECLIA</i>	1.9	mIU/mL	Women Follicular Phase : 2.4 - 12.6 Ovulation phase : 14.0 - 95.6 Luteal Phase : 1.0 - 11.4 Post Menopausal : 7.7 - 58.5 Men : 1.7 - 8.6
Follicle Stimulating Hormone-FSH <i>ECLIA</i>	4.3	mIU/mL	Men 1.5-12.4 Women Follicular Phase : 3.5 - 12.5 Ovulation phase : 4.7 - 21.5 Luteal Phase : 1.7 - 7.7 Post Menopausal : 25.8 - 134.8
LH / FSH Ratio	0.44		

Interpretation:

- Ratio of LH to FSH > 2.50 indicates the presence of PCOS.
- Polycystic Ovary Syndrome (PCOS) is a complex syndrome and each of the clinical phenotype is associated with different patterns of steroid hormones. It is likely that simultaneous measurement of multiple androgens (steroid/androgen profiling with highly specific and sensitive method LC-MS/MS) be more sensitive for detecting PCOS-related androgen excess and for predicting metabolic risk.
- Women with Non-classical Congenital Adrenal Hyperplasia (NC-CAH) due to 21-hydroxylase deficiency and women with PCOS have similar clinical presentation, with hyperandrogenism, oligomenorrhea, and polycystic ovaries. The screening tool to distinguish NC-CAH from PCOS is the basal 17-OHP levels and the ACTH stimulation test.

Comments:

Polycystic Ovarian Syndrome (PCOS) affects 5-10% of women of reproductive age, making it the most common endocrine disorder of women in this age group. It is characterized by amenorrhea, hirsutism and infertility. It is caused by a complex interaction of abnormalities in gonadotropins, androgens & estrogens. Insulin resistance and hyperinsulinemia contribute significantly to its pathophysiology. Although PCOS is associated with hyperandrogenism & infertility early in life, it is a harbinger of a lifelong condition that can lead to serious sequelae such as Endometrial or Ovarian cancer, Diabetes mellitus & Coronary artery disease. Thus, it is crucial to diagnose PCOS early in its course not only to recognize but also to delay or arrest its metabolic sequelae

*** End Of Report ***

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
 Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

Name: Mr MR.DUMMY Patient ID: 8052846 Gender: M Age: 23

Health Advisory

● Normal (N) ● Low (L) ● Borderline (BL) ● High (H)



Diabetes

This panel is used to check how much glucose/sugar there is in your blood. Too much blood glucose might indicate diabetes.

HbA1c (Glycosylated Haemoglobin): 7%

● HIGH

HbA1c is your average blood glucose (sugar) levels for the past three months.



One of the ways to control and reduce your HbA1c level - is to change your diet. Generally, foods that are high in carbs increase your blood sugar significantly. Also, foods that are high in fiber keep your glucose level in check.

Additionally, keeping your portion sizes *small* could prevent sharp rises in your blood sugar.

Some high-Carb foods to avoid



WHITE BREAD



POTATOES

Some high-Fiber foods to choose from



APPLES



CABBAGE



Fertility Profile

In general, fertility is the ability to produce children. However, the hormones involved in fertility are responsible for various other functions of the body as well. It is important to have healthy levels for overall wellbeing.

Testosterone Total: 480.0 ng/dL

